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Abstract
Background: Gallbladder cancer (GBC) is a rare malignancy, yet certain groups are at higher risk.
Knowledge of predisposing factors may facilitate earlier diagnosis by enabling targeted investigations into
otherwise non-specific presenting signs and symptoms. Detecting GBC in its initial stages offers patients
their best chance of cure.
Methods: PubMed was searched for recent articles (2008–2012) on the topic of risk factors for GBC. Of
1490 initial entries, 32 manuscripts reporting on risk factors for GBC were included in this review.
Results: New molecular perspectives on cholesterol cycling, hormonal factors and bacterial infection
provide fresh insights into the established risk factors of gallstones, female gender and geographic
locality. The significance of polyps in predisposing to GBC is probably overstated given the known
dysplasia–carcinoma and adenoma–carcinoma sequences active in this disease. Bacteria such as Sal-
monella species may contribute to regional variations in disease prevalence and might represent powerful
targets of therapy to reduce incidences in high-risk areas. Traditional risk factors such as porcelain
gallbladder, Mirizzi's syndrome and bile reflux remain important as predisposing factors.
Conclusions: Subcentimetre gallbladder polyps rarely become cancerous. Because gallbladder wall
thickening is often the first sign of malignancy, all gallbladder imaging should be scrutinized carefully for
this feature.
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Introduction
Gallbladder cancer (GBC) is a rare malignancy, although certain
groups are more likely to develop this lethal disease.1–6 Knowledge
of groups at high risk should facilitate earlier diagnosis by allow-
ing targeted investigation into the otherwise non-specific symp-
toms and signs with which the disease most commonly presents.
Detecting GBC in its initial stages offers patients their best chance
for cure as spread to lymph nodes and dissemination occur quite
early in the course of the disease (the frequency of nodal involve-
ment is 12–20% in stage Ib tumours).7–9
The highest incidence of GBC is seen in females with gallstones
in geographic locations such as northern India and Chile.4
Increasing age is a well-established risk factor across regions.4
Dietary and environmental factors also clearly play various roles
(although directly causal agents are yet to be characterized) and
obesity increases the risk by 15–66%.4 Controversy regarding the
management of gallbladder polyps continues.5 In addition to
these well-established risk factors, recent data referring to the
significance of concomitant bacterial infection and hormonal
factors provide new insights into causality.
Materials and methods
A literature search was performed in PubMed. A query using the
search term ‘gallbladder cancer’ in literature published between
January 2008 and July 2012 produced an initial result of 1490
entries. Only manuscripts describing carcinogenic factors and
published in English were considered. Non-human and non-
clinical studies were excluded, as were duplicate series and stand-
alone abstracts. Only papers specifically addressing cases of GBC
were included; papers identified with the initial search strategy
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that focused on only advanced biliary cancer or cholangiocarci-
noma were excluded. The reference lists of each manuscript were
also searched to identify additional articles that might have been
missed with the initial search strategy.
Figure 1 illustrates the screening and inclusion procedures con-
ducted according to the PRISMA (preferred reporting items for
systematic reviews and meta-analyses) criteria. A total of 1302
articles were excluded based on their titles alone. The remaining
188 manuscripts were reviewed by two authors (CHCP and RTG)
for relevance to the study. In addition to the 32 studies included




The association between the presence of gallstones and GBC is
supported by Level II evidence (multiple-cohort studies). Stone
characteristics may also play a role and larger, heavier stones are
implicated in the occurrence of disease,15 as is the length of time
for which stones are present.6 The presence of bacteria in the bile
and gallstones in the gallbladder, and the synergistic consequence
of GBC is a relatively new concept of considerable interest.14
Some authors have recently questioned whether the presence of
gallstones is causative or merely correlative with regard to GBC.6
Certainly, the excretion by the liver of cholesterol into the bile
(with the subsequent formation of gallstones) can parallel the
hepatic excretion of other toxic compounds which may be carci-
nogenic.6 Patients genetically predisposed to gallstones as a result
of an accelerated cholesterol metabolism may therefore also be at
risk for excessive exposure of other toxic compounds to the gall-
bladder epithelium. Two candidates are the orphan nuclear recep-
tor (ONR) family and the adenosine triphosphate (ATP)-binding
cassette (ABC) transporter family.16 An interesting hypothesis
introduced by Venniyoor16 connects the lower incidence of hepa-
tocellular carcinoma and higher incidence of GBC seen in areas of
northern India and South America, with epithelial exposure to
aflatoxin. Overactivity of the ONR and ABC efflux pumps may
reduce the exposure time of hepatocytes to aflatoxin, but increase
the exposure of the gallbladder epithelium to the same agent, thus
resulting in the observed shift in the incidences of these two ana-
tomically related, but quite distinct, malignancies. If the function
of these or similar molecular mechanisms actually increases risk
for GBC, gallstone presence might simply reflect the overactivity
of these pumps and, rather than the gallstones themselves being
directly carcinogenic, the subsequently increased exposure to
some other carcinogenic compound might represent the actual
causative factor.16 Differences in environmental toxins would then
explain geographic variations in the incidence of GBC, despite
similar rates of cholelithiasis.16 This concept is still in its early
development, but appears worthy of further investigation.
Polyps
The underlying issues driving the management of patients with
gallbladder polyps concern the missing of a malignant diagnosis
and the interval development of GBC.5 Level III evidence (hetero-
geneous case series) is available for this. Precursor lesions of
tumours of the gallbladder and extrahepatic biliary ducts are,
however, relatively uncommon and are certainly less studied than
other gastrointestinal tract malignant precursors.
Although both an adenoma–carcinoma sequence and a
dysplasia–carcinoma sequence are thought to operate in the
context of GBC, the association between mass-forming pre-
invasive neoplasia (adenoma) with adenocarcinoma is weaker for
multiple reasons.1 Firstly, there is frequently no evidence of
adenomatous tissue in GBC specimens. Secondly, the apparently
indolent course of many incidentally detected adenomatous
lesions, which never progress to carcinoma, argues against a clear
malignant pathway of development.1 There is also no clear genetic
sequence, as is described, for example, in colonic neoplasia. It is
likely that the majority of occurrences of GBC arise from dysplas-
tic flat lesions, not adenomatous polyps, as the majority of GBCs
are morphologically flat and infiltrative, rather than polypoid in
character.1
Interestingly, Asian series often report much higher rates of
neoplastic polyps, with rates of GBC occurring in up to 15% of
patients,17 by stark contrast with Western series, in which such
reports are much rarer. For example, in a series of over 400
patients with polyps reported from the Memorial Sloan–Kettering
Figure 1 Flow chart showing the process by which manuscripts
were selected for this review
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Cancer Center, no cases of GBC and only a 2% rate of adenomata
were found.5 This may simply represent differing incidences of the
disease across continents.4,18 However, differences in definitions of
what is included in any series of gallbladder lesions (particularly
in terms of what is defined as a polyp and what is defined as a mass
lesion) can also dramatically skew results and may explain the
wide disparities in the rates observed. For example, the inclusion
of sessile lesions of the gallbladder wall of >30 mm in size and
pedunculated lesions of <10 mm will clearly result in a rate of
malignancy that differs from that observed in a series that
excludes the former lesion type.19 Large sessile masses are highly
likely to represent GBC.20 The point at which a lesion should no
longer be considered as a ‘polyp’ has yet to be clearly defined. A
sessile mass replacing the gallbladder is unlikely to be mistaken for
a benign polyp and its inclusion in studies that attempt to differ-
entiate benign from malignant lesions will introduce a bias result-
ing in a higher rate of malignancy than is truly attributable to
small pedunculated polyps. Studies that report malignancy rates
in relation to polyps should define the size-based criteria used to
establish the point at which a lesion ceases to be considered as a
polyp and instead is regarded as a mass lesion or GBC. Studies
assessing purely sessile lesions are lacking.
Predicting malignancy in polyps is difficult as the vast majority
will be benign. The single factor that remains significant in all
series is the increase in the rate of malignancy with increasing size
of lesion.3,19,20 The corollary is naturally that small lesions are more
likely to be benign. Even cohorts with particularly high percent-
ages of malignancy in small polyps (Kwon et al. reported a rate of
GBC of almost 10% for lesions of 10–20 mm in size20) describe a
malignancy rate of only 1.3% for polyps of <10 mm. The growth
rate of polyps has not been found to be helpful in differentiating
neoplastic from non-neoplastic polyps21 and although other
authors have suggested that newer imaging modalities can be used
to detect subtle characteristics of polyps,22 there is no easily
applied, unambiguous, definitive diagnostic characteristic that is
sensitive and specific for neoplastic gallbladder polyps.
Spending inordinate amounts of time scrutinizing and agoniz-
ing over polyps, especially those of <10 mm in size, in order to
pick out the 1% of malignant lesions is of questionable value,
particularly in Western centres, in which the rate of malignancy is
even lower.5 For many surgeons, the level of suspicion is far lower
when preoperative gallbladder wall thickening is detected and,
although this is a significantly more common radiological finding
in GBC, it may be overlooked, with the result that patients are
scheduled for laparoscopic cholecystectomy without further con-
sideration. In general, incidental polyps of <10 mm are highly
unlikely to harbour malignancy and can safely be managed
expectantly.3
A more thoughtful approach would be to consider the pre-test
probability of a particular polyp being malignant, and to tailor
investigation and management accordingly. As Aldouri et al. have
elegantly reported,2 the prevalence of malignancy in patients with
gallbladder polyps was found to be significantly higher among
patients in a high-risk group (subjects with an Indian ethnic back-
ground) compared with White subjects living in the UK (5.5%
versus 0.08%). Risk stratification based on these types of consid-
eration is much more likely to enable the appropriate selection of
patients who require further investigation and intervention versus
those who can be safely reassured.
Another subgroup of patients with polyps who are at higher
risk for the development of GBC includes those with primary
sclerosing cholangitis (PSC). This disease is known to increase the
risk for GBC1 and, as Eaton et al.23 have suggested, it may be
reasonable to lower the threshold for polyp size to 8 mm in
patients with PSC. In that series of 57 patients with PSC the
authors identified a high rate of post-laparoscopic cholecystec-
tomy morbidity (33%) and no malignancy in polyps of <8 mm.23
They concluded that observation might be appropriate in patients
with polyps of <8 mm in the absence of other concerning imaging
or clinical features.23
Although there is no known association between GBC and
acromegaly, an increased rate of polyps was recently reported in
patients with this pituitary tumour (29% versus 4.6% in control
subjects).24 This patient group is known to be at increased risk for
colonic polyps and adenocarcinoma, but this is the first report to
link gallbladder polyps with acromegaly. The significance of this
finding remains unclear because all of the measured polyps were
small (<6 mm). Further studies assessing risk for GBC in patients
with acromegaly may well be justified, although it is extremely
unlikely that these polyps are of any clinical significance based on
size alone.
The role of bacteria
Knowledge of the carcinogenic influence of bacteria in GBC is
limited to Level V evidence. In their excellent overview of the role
of bacteria in carcinogenesis, Nath et al.25 outline two main path-
ways by which bacteria may play a role in the development of
malignancy. Firstly, chronic inflammation caused by persistent
bacterial infection may lead to carcinogenesis; alternatively, bac-
terial toxins and other metabolites may themselves be sufficiently
carcinogenic to result in malignancy.
The biliary tract has been described as the ‘consummate
example of inflammation-associated carcinoma’.1 However, the
role in the process played by bacteria has been less thoroughly
investigated. Both of the mechanisms described by Nath et al.25
may be significant for the causation of GBC. Stasis associated
with cholelithiasis promotes bacterial infection. The combined
effects of chronic mechanical irritation caused by stones and
chronic inflammatory change associated with colonization (or
subclinical secondary infection) may certainly be sufficiently car-
cinogenic to result in GBC.14 This might also explain why rates of
GBC do not exactly correlate with rates of cholelithiasis; that is,
an additional carcinogenic factor acting along with the stones
may be necessary.16
There are also a number of potential routes by which various
toxins and metabolites associated with bacterial infection may be
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implicated in the development of malignancy. Firstly, bacterial
infection is known to promote the development of carcinogenic
secondary bile acids via the action of the enzyme glucuronidase,
which is known to be produced by bacteria such as Salmonella
species.14 Secondly, glucuronidase can also deconjugate the glu-
curonide moiety from other xenobiotic and endogenous toxins
metabolized by the liver and, in doing so, reactivate them.16 The
natural concentrating function of the gallbladder might then
amplify the carcinogenic effect exerted by these mediators.25
Salmonella typhi is a prime candidate for bacterial predisposi-
tion to GBC.4,25 In addition to the theoretical implication outlined
above, empiric evidence is derived from the finding that Salmo-
nella was the most common isolate in bile from a group of patients
with GBC [in 16 of 40 patients (40%)] and was seen five times
more commonly than in a comparison group of patients with
simple cholelithiasis (8%).14 Culture-positive bile was more
common in patients with GBC (65% of patients) than in either
patients with simple cholelithiasis (42%) or control subjects
without cholelithiasis (12%) in a high-risk area in northern
India.14 Global variations in the epidemiology of GBC also corre-
late strongly with rates of cholelithiasis and Salmonella infection.26
Certain Helicobacter species have also attracted attention (Helico-
bacter bilius and Helicobacter hepaticus),27 although the support-
ing evidence is significantly weaker.4
Hormones
Female subjects are at increased risk for cholelithiasis and also
have an increased risk for GBC [odds ratio (OR): 2–8].4 Whether
this reflects only the incidence of gallstones (or whether there is a
separate hormonal influence) remains to be proven, but multiple
case–control and cohort studies have assessed female hormones
and GBC and indicate that, overall, female hormones are likely to
increase risk (based on Level III evidence).4 A recent case–control
study of 78 women with and without GBC performed in India
demonstrated a significantly increased risk for carcinogenesis in
women with a younger age of menarche, greater number of preg-
nancies and older age at menopause28 and thus a longer duration
of exposure to female sex hormones. Hormone replacement
therapy (HRT) and use of oral contraceptives have both been
linked to risk for GBC.29 An Italian case–control study of 31 GBC
patients and 3702 control subjects suggested that women previ-
ously treated with HRT had an increased risk for GBC [OR = 3.2,
95% confidence interval (CI) 1.1–9.3], which appeared to increase
with longer durations of therapy.30 During a prospective,
population-based study of over 60 000 Chinese women, 54 devel-
oped GBC and oral contraceptive use was shown to increase risk
(OR = 2.38, 95% CI 1.26–4.49).31
Park et al.32 identified that variants of the CYP1A1 gene, which
plays a role in steroid hormone synthesis, were associated with
both GBC and cholangiocarcinoma. The oestrogen and proges-
terone receptor status of resected GBC tissue has been examined
on multiple occasions, frequently with conflicting results, as
recently summarized by Barreto et al.33 These inconsistencies in
receptor expression are more likely to represent diverse tumour
biologies than the true absence of association and deserve further
investigation.
There is also evidence that female gender and prolonged oes-
trogen exposure can result in the increased export of cholesterol
and xenobiotics into bile.16 The toxic effect resulting from this
might well underpin any potential link that may exist between
gender and cancer. It is known that cholesterol per se can cause
dysplasia of the gallbladder epithelium so that, independently of
the formation of stones and hormones, increased cholesterol
cycling in females may predispose to malignancy.16 Geographic
variations in the incidence of GBC are more pronounced in
women,4 and this too may be explained by a physiologic concen-
trating effect of enhanced hepatic excretion present in women that
would magnify the potential carcinogenicity of any environmen-
tal toxins.
Historical and new risk factors
The radiographic finding of porcelain gallbladder has tradition-
ally been considered a risk factor for GBC. A recent systematic
review and case series including work published as far back as
1923 identified 140 cases of porcelain gallbladder in 60 665 chole-
cystectomies reported in seven studies (incidence: 0.2%).34 The
rate of GBC among subjects with porcelain gallbladder was 15%,
which, although the authors concluded it to be insufficiently high
to warrant prophylactic cholecystectomy, is nonetheless nearly
100 times higher than the 0.11% rate of GBC reported in associa-
tion with simple cholelithiasis.2 By contrast, none of the 13
patients with porcelain gallbladder in the case series included in
this systematic review34 and, similarly, none of 12 patients with
porcelain gallbladder reported in another contemporary series
from South Korea35 had GBC. However, these two studies respec-
tively included 35 and 117 patients with GBC, none of whom
displayed any feature of porcelain gallbladder.34,35 With careful
preoperative cross-sectional imaging using computed tomogra-
phy or magnetic resonance imaging, in addition to ultrasound,
and with the subsequent exclusion of T-stage II or III GBC, the
laparoscopic route also need not be contraindicated in porcelain
gallbladder, although it is potentially more difficult than cholecys-
tectomy for non-porcelain gallbladder.
Mirizzi’s syndrome represents another historical correlate of
GBC. A recent case report described a patient in whom the malig-
nancy was considered to be directly responsible for the syndrome
by causing a previously mobile gallstone to become progressively
impacted into the gallbladder neck and to compress the common
hepatic duct as the cancer grew.36 The disproportionately high rate
of Mirizzi’s syndrome in other series of GBC patients (five inci-
dences of GBC in 18 patients with Mirizzi’s syndrome13) may
reflect misdiagnosis wherein a GBC invading the porta hepatis is
mistaken for gallstone-related pathology, but this case report36
clearly described the genuine coexistence of the two conditions.
Chronic reflux of enteric contents or pancreatic juice is thought
to underlie the higher rate of cholangiocarcinoma following
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bilioenteric anastomoses, and the higher rates of both cholangi-
ocarcinoma and GBC in association with an anomalous pancrea-
ticobiliary duct junction (APBDJ) and/or choledochal cyst.11,37 In
a recent case report, GBC was described as a longterm complica-
tion of cholecystoenteric anastomosis, probably caused by the
same mechanism by which bilioenteric anastomosis predisposes
to cholangiocarcinoma.37 Cholecystoenteric anastomosis is rare
and is most commonly used in the setting of advanced malignancy
for palliation. This bypass should not be performed in benign
disease. Similarly, in a small study of children followed after cor-
rection of an APBDJ, all patients were found to have chronic
inflammatory changes in the gallbladder, which may underlie a
predisposition to subsequent GBC in such patients.38 In addition,
in a Japanese study, seven of 26 patients with an APBDJ developed
GBC, and seven of 48 patients with GBC were found to demon-
strate this anatomical variant.39
Although adenomyomatosis is not thought to predispose to
GBC, the presence of this pathological feature was found to be
associated with more advanced T (tumour) and N (node) stages
of malignancy in an analysis of 97 patients with GBC (in 25 of
whom GBC was associated with adenomyomatosis).40 Adenomyo-
matosis may be identified using ultrasound, in which the gallblad-
der wall is shown to be thickened (segmental or diffuse) and may
contain anechoic or echogenic foci, known as the ring-down
reverberation artefact.12 Whether the progression of GBC leads to
the development of adenomyomatosis in these cases or whether
there is some association between Rokitansky–Aschoff sinus
development and malignancy remains unclear. Until further data
are available, the implication for clinical practice may be only that
the preoperative detection of adenomyomatosis should perhaps
stimulate further imaging to exclude GBC. Unfortunately, the dif-
ferentiation of adenomyomatosis from GBC on imaging is
extremely difficult.41
Conclusions
New insights into factors that predispose patients to GBC should
help identify people at high risk for this disease and support
appropriate investigations and treatment in these subjects at an
earlier point in the natural history of the disease. Less concern
about small polyps seems appropriate because the vast majority of
these lesions do not become GBC. Gallbladder cancer more com-
monly arises from dysplastic, rather than adenomatous, lesions.
Knowledge of the intriguing role that bacteria may play in the
pathogenesis of this disease may prove to be a powerful weapon
should more evidence accumulate implicating chronic infection
by bacteria such as those of Salmonella species. Further under-
standing of the molecular events involved in cholesterol metabo-
lism may also uncover more of the mechanical bases of the
development of GBC. Finally, the traditional risk factors of por-
celain gallbladder and Mirizzi’s syndrome, as well as the signifi-
cance of bile reflux following bilioenteric bypass or in association
with an APBDJ, should also be kept in mind as these patients
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